Edition:
United States

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

12.30USD
23 Apr 2018
Change (% chg)

$-1.14 (-8.48%)
Prev Close
$13.44
Open
$13.44
Day's High
$13.44
Day's Low
$12.28
Volume
255,720
Avg. Vol
280,004
52-wk High
$15.59
52-wk Low
$3.16

Latest Key Developments (Source: Significant Developments)

Cymabay Reports Q4 Loss Per Share $0.11
Thursday, 15 Mar 2018 04:01pm EDT 

March 15 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.11.Q4 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.QTRLY COLLABORATION REVENUE $5.2 MILLION.  Full Article

Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA.  Full Article

CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Friday, 29 Dec 2017 05:08pm EST 

Dec 29 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

CymaBay reports Q3 loss per share $0.21
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - CymaBay Therapeutics Inc ::CymaBay reports third quarter 2017 financial results and corporate updates.Q3 loss per share $0.21.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.CymaBay Therapeutics - ‍cash, cash equivalents and marketable securities totaled $102.2 million at end of Q3 of 2017, compared to $17.0 million at Dec 31, 2016​.CymaBay Therapeutics Inc - ‍existing cash expected to fund operations into 2019​.  Full Article

Cymabay Therapeutics names Sujal Shah CEO
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces the appointment of Sujal Shah as president and chief executive officer.Cymabay Therapeutics Inc says ‍sujal Shah has been serving as interim president and chief executive officer since March 2017​.  Full Article

Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting.Cymabay Therapeutics - ‍interim Phase 2 study results demonstrate potential for superior efficacy, better tolerability over existing second-line therapy​.  Full Article

CymaBay Therapeutics reports Q2 loss per share $0.31
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - CymaBay Therapeutics Inc -:CymaBay reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.31.Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

CymaBay announces pricing of public offering of common stock
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - CymaBay Therapeutics Inc -:CymaBay announces pricing of public offering of common stock.Says public offering of 13.0 million common shares priced at $6.50 per share.  Full Article

Cymabay announces proposed public offering of 10.0 mln common shares
Monday, 17 Jul 2017 04:14pm EDT 

July 17 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces proposed public offering of common stock.Says offering 10.0 million common shares.Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar.Cymabay Therapeutics Inc - ‍intends to offer and sell 10 million shares of its common stock in an underwritten public offering​.  Full Article

CymaBay announces positive interim results from low-dose phase 2 study of seladelpar
Monday, 17 Jul 2017 07:30am EDT 

July 17 (Reuters) - Cymabay Therapeutics Inc ::CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis.CymaBay Therapeutics Inc says strong reduction in alkaline phosphatase of 39pct (5 mg) and 45pct (10 mg) at week 12.CymaBay Therapeutics Inc says FDA agrees to extend dosing of 5 mg and 10 mg beyond six months.CymaBay Therapeutics Inc says potential for superior efficacy and better tolerability than existing second-line therapy in study.CymaBay Therapeutics Inc says in study there were no serious adverse events and no safety transaminase signal was observed at either dose.CymaBay Therapeutics Inc says fda has agreed to allow continuation of seladelpar treatment beyond six months for 5 mg and 10 mg doses.  Full Article

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018